Condition
Advanced Lymphoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 8 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
8 shownAt-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced CancerNCT05969860 · 2023-08-23
RECRUITINGTesting Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)NCT06385483 · 2018-02-28
ACTIVE_NOT_RECRUITINGTesting GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)NCT04439175 · 2016-02-25
ACTIVE_NOT_RECRUITINGTesting Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)NCT04439292 · 2016-01-04
ACTIVE_NOT_RECRUITINGTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17
ACTIVE_NOT_RECRUITINGTesting Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)NCT04439110 · 2015-08-12
ACTIVE_NOT_RECRUITINGTesting Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)NCT04439253 · 2015-08-12
ACTIVE_NOT_RECRUITINGTesting Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)NCT04439266 · 2015-08-12
ACTIVE_NOT_RECRUITINGCommon interventions
CrizotinibDRUG3AfatinibDRUG2Biopsy ProcedurePROCEDURE2Biospecimen CollectionPROCEDURE2Computed TomographyPROCEDURE2Dabrafenib MesylateDRUG2Echocardiography TestPROCEDURE2Magnetic Resonance ImagingPROCEDURE2Radionuclide ImagingPROCEDURE2TaselisibDRUG2Trastuzumab EmtansineBIOLOGICAL2AdavosertibDRUG1Afatinib DimaleateDRUG1BinimetinibDRUG1CapivasertibDRUG1Clinical EncounterPROCEDURE1CopanlisibDRUG1Copanlisib HydrochlorideDRUG1Cytology Specimen Collection ProcedureOTHER1DabrafenibDRUG1DasatinibDRUG1DefactinibDRUG1Defactinib HydrochlorideDRUG1ErdafitinibDRUG1FexagratinibDRUG1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING7
RECRUITING1
Phase mix
PHASE28
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.